IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.
- Sales of € 2.8 million, a 10% increase vs. H1 2015
- Operational result +14%
Significant scientific & business advances
- Partnership agreement with Greater Paris University Hospital (AP-HP) to set up a common sequencing platform
- International presentation of new results on IntegraGen’s biomarker for optimizing treatment of patients with metastatic colorectal cancer